NR1H4 and metabolic dysfunction-associated steatotic liver disease: In support of this hypothesis, therapeutic benefits have been observed with IVM on nonalcoholic fatty liver disease, hyperglycemia, and lipidemia using in vitro and in vivo models, and these preclinical benefits are likely related to the activity of IVM on hepatic farsenoid X receptors (FXR) [66,67,68].